TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
2.220
-0.070 (-3.06%)
Jun 27, 2025, 4:00 PM - Market closed
TuHURA Biosciences Employees
TuHURA Biosciences had 19 employees as of December 31, 2024. The number of employees increased by 18 or 1,800.00% compared to the previous year.
Employees
19
Change (1Y)
18
Growth (1Y)
1,800.00%
Revenue / Employee
n/a
Profits / Employee
-$1,288,099
Market Cap
96.97M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19 | 18 | 1,800.00% |
| Dec 31, 2023 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
HURA News
- 4 days ago - TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma - PRNewsWire
- 4 days ago - TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals - PRNewsWire
- 19 days ago - FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma - PRNewsWire
- 25 days ago - TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy - PRNewsWire
- 26 days ago - TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting - PRNewsWire
- 6 weeks ago - TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 6 weeks ago - TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference - PRNewsWire
- 7 weeks ago - TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP) - PRNewsWire